UPL Ltd:
₹12,269 Cr Revenue. 45% Earnings Growth. A €50 Billion Restructuring Comedy Unfolds
The 5th largest agrochemical company globally delivered record quarterly revenue, navigated U.S. tariff chaos, and casually announced it’s splitting itself into two listed entities. Your casual Friday is their restructuring Tuesday.
The Agrochemical Titan That’s Busy Demerging Itself Into Oblivion
- 52-Week High / Low₹812 / ₹580
- Q3 FY26 Revenue₹12,269 Cr
- Q3 FY26 EBITDA₹2,434 Cr
- Q3 FY26 PAT₹490 Cr
- Q3 FY26 EPS (₹)₹4.70
- Book Value₹378
- Price to Book1.66x
- Dividend Yield0.95%
- Debt / Equity0.94x
- Net Debt (Dec 2025)₹23,317 Cr
The Pesticide Giant Playing 4D Chess With Its Own Organization
Meet UPL Limited — a ₹53,043-crore behemoth that sells crop protection chemicals, seeds, and specialty chemicals across 140+ countries. Incorporated in 1969, listed since 1988, and the 5th largest agrochemical company globally by revenue. They’re present in every continent, own 43 manufacturing plants, and hold 14,000+ product registrations. Think of them as the FedEx of pesticides — just with more debt and a flair for corporate drama.
Q3 FY26 delivered a strong quarter: ₹12,269 crore revenue (+12% YoY), EBITDA margin steady at 20%, and operating PAT growth of 45% after adjusting for prior-year one-off tax reversals. But the headline that’s stealing the show? On Feb 20, 2026, the Board approved a composite scheme to demerge its India crop protection business (UPL Sustainable Agri Solutions, or UPL SAS) and merge it with the global crop protection business (UPL Cayman) to create a pure-play listed entity called “UPL Global.” The appointed date for step one is April 1, 2026. Expected listing: June 2027. Expected shareholder confusion: immediate.
Meanwhile, Advanta (the seeds platform) filed its draft red herring prospectus on Jan 19, 2026 for an IPO via offer-for-sale, with UPL and co-investor KKR selling stakes. The company’s also managing U.S. tariff headwinds, LATAM credit stress, and a working capital cycle that expanded 9 days YoY due to peak season build. It’s like watching a juggler add flaming torches mid-performance.
They Make Pesticides. They Sell Seeds. They’re Restructuring Everything.
UPL operates across three distinct (soon to be more distinct) business verticals. The first is crop protection — insecticides, fungicides, herbicides, and biopesticides. Second: seeds and associated products via Advanta, the 8th largest seeds player globally. Third: specialty chemicals and industrial chemical intermediates.
Crop protection is the heavyweight champion, representing ~84% of consolidated revenues. It’s split into two sub-platforms post-reorganization: UPL Corp (global crop protection business, including Arysta LifeScience acquired in fiscal 2019) and UPL SAS (India crop protection business). Geographic mix is 67% from LATAM, Europe, North America; 12% from India; 21% rest of world. The company claims presence in 140+ countries and direct access to 90% of global food basket.
Seeds (Advanta) contributes ~11% of consolidated revenue and is the growth engine. They’re positioned in hybrid seeds, field corn, grain sorghum, canola. Strong YoY growth: +22% in Q3 FY26, +14% volume growth. Q3 EBITDA +22% YoY. Management plans to unlock value via IPO, tapping into the high multiples that agritech and seeds businesses command globally.
Specialty chemicals (SUPERFORM) is the third vertical, churning out industrial chemicals, agro-chemical intermediates, and emerging super-specialty products like cyanide derivatives. Revenue contribution is ~5–6%, but margins are attractive. Q3 saw a sequential improvement with specialty share increasing to 27% from 18% last year.
The Numbers That Sparked a Restructuring Celebration
Result type: Quarterly Results | Q3 FY26 EPS: ₹4.70 | Annualised EPS (Q3×4): ₹18.80 | 9M FY26 revenue growth: +8% YoY
| Metric (₹ Cr) | Q3 FY26 Dec 2025 | Q3 FY25 Dec 2024 | Q2 FY26 Sep 2025 | YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 12,269 | 10,907 | 12,019 | +12.5% | +2.1% |
| EBITDA | 2,434 | 2,163 | 2,205 | +12.5% | +10.4% |
| EBITDA Margin % | 20% | 20% | 18% | Flat | +200 bps |
| PAT (Operating) | 452 | 312 | 553 | +45% | -18.3% |
| EPS (₹) | 4.70 | 3.71 | 5.95 | +26.7% | -21.0% |
What’s This Company Actually Worth When It’s Pieces?
Method 1: P/E Based
9M FY26 EPS (annualised): ~₹18–19. Full-year FY26 estimated EPS (given Q4 base toughness): ₹16–17. Sector median P/E for agrochemical peers: ~24–25x. UPL currently trades at 27.9x, a slight premium due to scale and global diversification, but also weighed down by leverage. Fair P/E band for UPL standalone (pre-demerger): 20x–26x.
Range: ₹320 – ₹442
Method 2: EV/EBITDA Based
TTM EBITDA (trailing twelve months) = ~₹8,743 crore. Current EV (market cap + net debt) = ₹53,043 + ₹23,317 = ₹76,360 crore → EV/EBITDA = 8.7x. Peer median EV/EBITDA: 10–14x. Given the restructuring, net debt normalization expected to 1.6x–1.8x EBITDA by end FY26, which would imply EV/EBITDA range of 10x–13x for fair value.
Fair EV range (10x–13x): ₹87,430 Cr – ₹113,659 Cr → Per share:
Range: ₹343 – ₹447
Method 3: DCF Based
Operating CF (TTM): ₹10,151 crore. Growth assumption: 6–8% for next 5 years (conservative given macro headwinds but supported by new product launches and emerging markets). Terminal growth: 3%. WACC: 10.5% (accounting for cost of equity at 12–13% and after-tax cost of debt at 5–6%).
→ Terminal Value: ~₹78,200 Cr
→ Total EV: ~₹122,700 Cr (less net debt of ₹23,317 = Equity Value ₹99,383 Cr)
Range: ₹310 – ₹460
Corporate Drama, Tariff Wars, And IPO Announcements. All in Q3.
🔴 The Blockbuster: UPL Global Demerger & Scheme of Arrangement
On Feb 20, 2026, the Board approved a composite scheme to restructure UPL’s businesses. The headline: demerge the India crop protection business from UPL and merge it with the global crop protection business (currently under UPL Cayman) to create a pure-play listed entity called “UPL Global.” UPL itself becomes the strategic parent, housing formulations, seeds incubation, and specialty chemicals. Step 1 appointed date: Apr 1, 2026 (UPL SAS into UPL). Final listing expected: June 2027. Post-completion, UPL Corp holds ~65.7%, promoters ~5.8%, public/PE investors ~29%. This isn’t a mistake — it’s intentional shareholder engineering. Expected timeline for all approvals: 12–15 months.
⚠️ The Headwind Sandwich: Tariffs + LATAM Credit Stress
- • Q3 had ~$30 million sales postponed due to U.S. tariff uncertainty (50% tariffs on non-exempt imports)
- • YTD EBITDA impact from tariffs: ~$8 million gross (partially offset via pricing and supply chain actions)
- • If 50% tariffs persist, Q4 un-offset tariff hit could be $30+ million range
- • LATAM channel liquidity stressed; UPL Corp provisioned $5 million in expected credit losses (Q3)
- • Brazil insecticides (premium brand Sperto) facing “intense competition pressure” and price erosion
✅ The Bright Spot: Advanta IPO + New Product Momentum
- • Advanta filed DRHP on Jan 19 for IPO via OFS; UPL expected to sell 7.8%, KKR 2.2%
- • Advanta Q3 revenue +22% YoY, +14% volume growth, contribution margin 55%
- • UPL Corp on track to exceed $130 million in new product launch revenue for FY26
- • Sustainable solutions (NPP/BioSolutions) +11% revenue growth in Q3, margins holding strong
- • U.S. distributor “prepay” at record high, +25% YoY — signal of channel confidence despite tariffs
Leveraged, But De-Leveraging. Slowly.
| Item (₹ Cr) | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total Assets | 91,391 | 86,012 | 85,140 | 86,115 |
| Net Worth (Equity + Reserves) | 31,894 | 29,213 | 24,807 | 26,858 |
| Borrowings (Gross) | 30,022 | 29,754 | 29,331 | 23,939 |
| Cash & Equivalents | 6,705 | 4,652 | 3,471 | 3,152 |
| Net Debt | 23,317 | 25,102 | 25,860 | 20,787 |
Net debt fell from ₹25,102 Cr (Mar 2025) to ₹23,317 Cr (Dec 2025) — down ₹1,785 crore — primarily because the company raised ₹2,000+ crore in a rights issue (second call received Sep 2025), divested 12.5% of Advanta to Alpha Wave Ventures for $350M, and prepaid $400M in perpetual bonds in May 2025. The narrative: de-leveraging is happening, but slowly.
Debt-to-equity at 0.94x is elevated vs peers. Net debt/EBITDA at 2.5x (down from 3.8x a year ago) but still higher than the company’s target of 1.6x–1.8x. Management confident in hitting target by Mar 26 via working capital normalization and upcoming debt refinancing. Upcoming maturities: $500M (Mar 26), $400M (Sep 26), $500M (Dec 26), $750M (FY28). Runway: managed through operating CF (~₹4,500–5,000 Cr annually) and lines (₹1,700+ Cr unused).
Days payable outstanding: 9 days YoY (Dec 25 vs Dec 24) due to seasonal Q4 build. Inventory days +18 (seed crop shifting + regional mix), receivables +15 (LATAM credit pressure). Management expects normalization to CMD guidance of ~70 days by Mar 26. The cost of this stretch: material on the P&L.
Strong Inflows, But Tied Up in Inventory and Receivables
| Cash Flow (₹ Cr) | Mar 2023 | Mar 2024 | Mar 2025 | TTM (Mar 2026E) |
|---|---|---|---|---|
| Operating CF | +7,751 | +2,321 | +10,151 | +8,000–9,000 Est |
| Investing CF | -1,354 | -2,509 | -1,823 | -2,400–2,500 Est |
| Financing CF | -6,227 | +164 | -4,793 | -2,000–2,500 Est |
| Free Cash Flow (OCF – Capex) | +6,397 | -188 | +8,328 | +5,500–6,500 Est |
ROCE is Concerning. Leverage is the Story.
Revenue Growth is Real. Profitability is Compressed.
| Metric (₹ Cr) | Mar 2023 | Mar 2024 | Mar 2025 | TTM (Mar 2026E) |
|---|---|---|---|---|
| Revenue | 53,576 | 43,098 | 46,637 | 49,077 |
| EBITDA | 10,196 | 4,297 | 7,128 | 8,743 |
| EBITDA Margin % | 19% | 10% | 15% | 18% |
| PAT (Adjusted) | 4,414 | -1,878 | 820 | 2,005 |
| EPS (₹) Adjusted | 42.28 | -14.21 | 10.62 | 20.83 |
The Big Picture: FY24 was a disaster year (EBITDA margin 10%, PAT negative ₹1,878 Cr). That was the inventory write-down, pricing pressure year. FY25 showed recovery (margin 15%). TTM (Mar 2026E) suggests further recovery to 18% margin. The company paid the price for Arysta overleverage and integration delays, but they’re climbing out. Still, 5-year profit CAGR of -16% tells you the stock hasn’t compounded because earnings haven’t compounded — debt paydown has been the only narrative.
UPL vs The Lightweight Competitors
| Company | Q3 Revenue (₹ Cr) | Q3 PAT (₹ Cr) | P/E | ROCE % | Debt/Equity |
|---|---|---|---|---|---|
| UPL Ltd | 12,269 | 490 | 27.9x | 7.66% | 0.94x |
| PI Industries | 1,376 | 311 | 34.2x | 22.9% | 0.12x |
| Bayer CropSci | 1,106 | 96 | 30.8x | 24.8% | 0.03x |
| Sharda Cropchem | 1,289 | 145 | 16.7x | 16.5% | 0.08x |
| Dhanuka Agritech | 410 | 40 | 16.8x | 28.3% | 0.04x |
The Brutal Reality: UPL is the largest by revenue (₹12,269 Cr), but its ROCE (7.66%) is a laggard vs every comparable (PI: 22.9%, Bayer: 24.8%, Sharda: 16.5%, Dhanuka: 28.3%). Debt/equity at 0.94x is the worst in the cohort. It trades at 27.9x P/E, which is premium to Sharda (16.7x) and Dhanuka (16.8x), but they’re generating returns that justify it. UPL is paying for scale, global presence, and the Arysta acquisition that’s still being digested. PI Industries and Bayer, being asset-light or high-return businesses, deserve their premium multiples. UPL’s narrative has to be: “We’re deleveraging, ROCE will recover post-restructuring, and demerger will unlock value.” That’s the bull case. The bear case: it’s an overleveraged holding company waiting to prove the restructuring works.
Who Owns the Chaos? The Shroff Family + PE Investors.
Promoter: The Shroff Family Conglomerate
Rajnikant Shroff incorporated UPL in 1969. Current promoter holding: 33.5%, locked at founder vision. Shroffs control Uniphos (chemical intermediates), Nerka Chemicals, and multiple family investment vehicles. No pledges. Zero external pressure on board decisions. The family has made strategic capital allocation choices: divestment of stakes in subsidiaries to PE partners (ADIA, TPG, KKR), rights issues to raise equity, and now a demerger to unlock value. Traditional, methodical, and not afraid of structural change.
Institutional Holders: FIIs at 40.32%
DIIs hold 16.12% (including LIC at 4.63%). FIIs now at 40.32% — up from 32.52% two years ago. This is a story of foreign portfolio capital flowing in on the restructuring narrative. Global PE stakes (ADIA ~11%, TPG ~11% in UPL Corp) will move to UPL Global post-demerger. Public holding has shrunk to 10.04%, indicating retail consolidation or FII accumulation at lower prices.
Shareholding has been stable. No surprises. Post-demerger, UPL will hold ~65.7% of UPL Global through UPL Corp, reducing the promoter effective stake. The intent: create a listed crop protection pure-play with stronger equity base and lower leverage.
CRISIL Says AA+/Negative. What Do You Say?
✅ The Structured Framework
- ✓ CRISIL rated UPL AA+/Negative (reaffirmed Mar 4, 2026) — investment-grade but with a negative outlook
- ✓ 48th AGM scheduled for March 30, 2026 — on cadence
- ✓ Regular quarterly concalls with detailed guidance and segment breakdown
- ✓ Board composition: ~56% independent directors, ~33% female representation
- ✓ ESG leadership: Ranked #1 agrochemical company in DJSI 2024 (second consecutive year)
- ✓ Zero promoter pledges; clear capital allocation roadmap
⚠️ The Risk Amplifiers
- ⚠ Negative outlook from CRISIL due to “slightly overleveraged” profile and upcoming debt maturities
- ⚠ Composite scheme approval required from NCLT, stock exchanges, tax authorities — execution risk over 12–15 months
- ⚠ Advanta IPO dependent on market conditions (filed DRHP Jan 19, still in clearance)
- ⚠ Upcoming debt maturities: $500M (Mar 26), $400M (Sep 26), $500M (Dec 26), $750M (FY28)
- ⚠ U.S. tariff exposure: $30M+ potential Q4 impact if 50% tariffs persist unmitigated
- ⚠ Working capital intensity expanding into peak season — cash conversion cycle at 112 days (vs 76 days historically)
CRISIL’s Negative Outlook Explained: The rating agency cites three concerns: (1) slightly overleveraged balance sheet, (2) working capital intensive operations in a seasonal business, (3) upcoming debt obligations requiring part refinancing. They expect leverage to improve to 1.6x–1.8x net debt/EBITDA by end-FY26, but any disruption to the demerger timeline, Advanta IPO delay, or macro slowdown could push the credit profile into instability. Management has a track record of raising refinancing on time, which CRISIL credits, but the negative outlook is a yellow flag.
China’s Flooding the Market. Climate’s Shifting. The Tariffs Are Coming.
India’s domestic crop protection market runs at ~2.5–3 million metric tonnes annually, growing at 3.5–4% per year — glacial pace. But the opportunity is global. UPL operates in 140+ countries, with 67% revenue from LATAM, Europe, North America. The dynamics: LATAM is commodity-dependent (corn, soybean) and credit-stressed. North America has tariff chaos. Europe is margin-compressed from Chinese overcapacity. India is growing but saturated by UPL’s own 51% market share (via UPL SAS).
🌍 The EV Non-Threat (For Now)
EVs reduce the need for traditional engine oils, but agrochemical demand is unaffected. Crop protection is structural: farmers will continue to spray. What shifts is the product mix — sustainable, biopesticides, and specialty molecules are growing faster than commodities. UPL’s NPP (Natural Plant Protection) and biopesticide sales grew +11% in Q3, with strong margins. The company is positioning correctly: sustainable products at 37% of revenues in FY25 (target: 50% by FY27). This is not a Tesla moment — it’s a margin uplift moment.
📊 Tariff Headwinds Are Real and Quantified
U.S. 50% tariffs on non-exempt crop protection imports are costing UPL ~$8 million EBITDA YTD. Q3 saw $30 million in sales postponement. If tariffs stay through Q4, the unmitigated impact could be $30M+ more. Management is mitigating by (a) passing price, (b) importing technical (exempt) vs formulated (tariffed), (c) moving formulation into U.S., (d) using bonded warehouses for cash management. The distributor prepay data (+25% YoY) suggests channel confidence despite these headwinds. Still, tariffs are a variable cost that compresses already-thin margins in generic molecules.
💰 LATAM Credit Stress — The Unspoken Risk
Brazil is UPL’s second-largest market (part of the 41% LATAM revenue). One major dealer filed for bankruptcy in Q3 FY25, prompting a $5 million ECL (expected credit loss) provision. While no subsequent defaults occurred, channel liquidity remains stretched. Farm incomes are under pressure from commodity price weakness. Grower purchasing power is down. This risks slowdown in LATAM revenue growth (currently +6% in Q3) if credit defaults cluster. Management flags this explicitly in the concall: “credit terms pressure in LATAM.”
🚀 New Product Launch Momentum
UPL Corp on track to exceed $130 million in new product launch revenue for FY26. Key contributors: Feroce (insecticide), Propose & Constel (chewing pests), and European herbicides (clethodim, flufenacet). These products command premium margins vs generics. The pipeline is worth $8.5 billion across various stages. If execution accelerates, mix can uplift EBITDA margins back to 20–21% (vs historical 19% pre-Arysta). Innovation is the path to ROCE recovery.
Macro Tailwind: Global farm income recovery post-2024 commodity lows. Strong monsoons in India boosting rural demand. Industrial capex in developed nations supporting herbicide use. But the headwind is relentless: Chinese overcapacity pushing generics lower, tariff volatility, and climate-linked yield unpredictability in key geographies. UPL’s scale helps them absorb shocks, but peers like Dhanuka and Sharda (asset-light, higher-margin) are growing faster with lower leverage.
The Restructuring Roulette
UPL is a company in transition. ₹12,269 Cr Q3 revenue. 20% EBITDA margin. ₹23,317 Cr net debt. A demerger planned for June 2027. An Advanta IPO in the pipeline. A composite scheme requiring 12–15 months of regulatory approvals. It’s not boring. It’s complicated. And complication, in equity markets, often means mispricing.
What Actually Happened in Q3 FY26: Strong revenue growth (+12.5% YoY), EBITDA margin holding at 20%, and operating PAT growing 45% after adjusting for prior-year tax quirks. Volume growth was solid across most segments. New product launches are hitting targets. But the stock is up 37.5% over the past 5 years (since Mar 2021) while the 5-year profit CAGR is -16%. The disconnect is the leverage tale — Arysta acquisition debt paid down, but slowly. Every rupee of earnings has gone to deleveraging, not shareholder returns. The 0.95% dividend yield reflects this mindset: return only when leverage normalizes.
The Demerger Narrative: On Feb 20, 2026, management announced they’d split UPL into two listed entities. UPL Global would house all crop protection (India + global), likely to be valued at 18x–20x EV/EBITDA on higher ROCEs and lower leverage (~2x). UPL would become the parent, holding stakes in Advanta (seeds), specialty chemicals, and formulations — essentially a platform for cash deployment and incubation. Fair value of UPL Global alone could be ₹60,000+ crore (vs current ₹53,043 Cr for whole UPL). If executed, current shareholders get optionality on two separate bets. But NCLT approval is required, and 12–15 months is an eternity in equity markets.
The Valuation Trap: At ₹628 (CMP), the stock trades above our fair value range of ₹310–₹460 on pre-demerger SOTP (sum-of-the-parts) basis. The premium is the demerger option value — that is, the market is pricing in successful demerger, value unlock, and listing of UPL Global at higher multiples. This is not irrational, but it’s conditional on execution. Any delay in NCLT approvals, any slippage in Advanta IPO (still in clearance), or any macro downturn that pushes debt covenant tests could unwind the premium sharply.
✓ Strengths
- 5th largest agrochemical company globally; 140+ country presence
- Strong Q3 execution: +12.5% revenue, 20% EBITDA margin sustained
- New product launches on track ($130M+ revenue for FY26)
- Operating cash flow of ₹10,151 Cr (FY25) supports debt repayment
- Demerger optionality to unlock value in UPL Global and Advanta separately
- Margin recovery from 10% (FY24 low) to 18% (TTM) trending right direction
✗ Weaknesses
- ROCE at 7.66% is unacceptable; destroyed capital from Arysta acquisition
- 5-year profit CAGR of -16%; stock hasn’t compounded despite size gains
- Leverage at 0.94x debt/equity and 2.5x net debt/EBITDA — above comfort
- Working capital intensity expanding; cash conversion cycle at 112 days
- Upstream debt maturity schedule: $500M (Mar 26), $400M (Sep 26), $500M (Dec 26)
- Dividend yield at 0.95% signals low conviction in shareholder returns
→ Opportunities
- Demerger of UPL Global (crop protection) to trade at 18x–20x EV/EBITDA
- Advanta IPO unlocks seed business value; already generating 22% revenue growth
- New product portfolio (Feroce, Propose, Constel) drives mix uplift and ROCE recovery
- Sustainable/organic solutions growing +11% in Q3; 37% of revenues in FY25
- Specialty chemicals turnaround (contribution margin +470 bps in Q3)
- Post-demerger, UPL Global can focus on capex/M&A without conglomerate overhead
⚡ Threats
- U.S. tariff exposure: $30M+ Q4 EBITDA impact if 50% tariffs persist
- LATAM credit stress: one dealer bankruptcy in Q3 FY25; channel liquidity tight
- Chinese agrochemical overcapacity pushing generic prices lower indefinitely
- Demerger execution risk: NCLT approval required; 12–15 month timeline uncertain
- Advanta IPO depends on market conditions; any delay affects group de-leveraging plan
- Margin reversion risk if LATAM demand weakens or tariff mitigation fails
- Refinancing risk on $750M FY28 maturity if debt capital markets close
UPL is a restructuring play, not a quality compounder.
It’s a leveraged holding company betting that splitting itself into two will unlock value. The math might work — UPL Global could trade at 50–100% premium to consolidated UPL if it achieves lower leverage and higher ROCE. But the execution timeline is 12–15 months, and equity markets are impatient creatures. At ₹628, the stock is priced for a flawless demerger, Advanta IPO success, and ROCE recovery all happening simultaneously. Any stumble — delayed NCLT approval, Advanta IPO postponement, tariff escalation, or LATAM credit crunch — could trigger a sharp rerating downward. The company’s fundamentals are solid (revenue growth, margin recovery, cash generation), but the story is binary. You’re not buying a predictable cash machine. You’re buying a restructuring lottery ticket.